Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• GARDASIL 9 and GARDASIL do not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider

  60% confidence

• Data show long-term effectiveness of GARDASIL 9 and GARDASIL 14 years and 18 years, respectively, following vaccination with 3 doses

  60% confidence

• The duration of immunity of GARDASIL and a 2-dose schedule of GARDASIL 9 has not been established

  60% confidence

• Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV

  60% confidence

• GARDASIL 9 and GARDASIL have not been demonstrated to provide protection against diseases caused by HPV types not covered by the vaccine or HPV types to which a person has previously been exposed through sexual activity

  60% confidence

• Results from studies show vaccine effectiveness for at least 14 years following 3 doses of the 9-valent vaccine, and vaccine effectiveness up to 18 years after 3 doses of the quadrivalent vaccine against HPV 16/18-related high-grade cervical disease

  60% confidence

• Data on certain HPV-related oropharyngeal cancers highlight the importance of HPV vaccination in helping to prevent these cancers, which impact both women and men

  60% confidence

• Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV vaccination for females ages 9 to 45 years, beginning in adolescence

  60% confidence